SciSparc Ltd. announced it has signed an agreement with the Soroka University Medical Center, in Be'er-Sheva, Israel (‘Soroka Medical Center') to conduct the Company's clinical study for SCI-210 in patients suffering from autism spectrum disorder (‘ASD'). During 2022, the Company received approvals from the Israeli Ministry of Health as well as the Ethics Committee of the Soroka University Medical Center, in Be'er-Sheva, Israel, to conduct the Company's clinical trial. The trial will investigate the effect and safety of SciSparc's drug candidate SCI-210, a proprietary combination of cannabidiol (‘CBD') and CannAmide™, in comparison to CBD monotherapy in treating ASD.

The study's objectives are to evaluate the safety, tolerability and efficacy of SCI-210 in children with ASD in a randomized, double-blind, placebo controlled with cross-over study. The design of the study includes a 20-week, randomized double-blind placebo-controlled with cross-over clinical trial of 60 children. The trial has three primary efficacy end points: the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire; the Clinical Global Impressions-Improvement (CGI-I) performed by a clinician; and the effective therapeutic dose.

ASD is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social interaction and communication. The term ‘spectrum' in autism spectrum disorder refers to the wide range of symptoms and severity.